ESPO® / NESP®
ESPO® is a glycoprotein, human erythropoietin, produced by using the technology of genetic recombination. Its specific pharmacological effect of increasing erythrocytes allows it to act as an anemia-relieving treatment for renal anemia.
NESP® is an erythropoiesis stimulating agent (ESA) with longer-lasting effect than conventional erythropoietin drugs. It is effective for improving renal anemia with reduced administration frequency. Merits including outstanding effectiveness in correcting anemia, along with a flexible dosage amount and interval, have earned the trust of the pharmaceutical marketplace and given this useful drug a leading market share.
Marketed by Kyowa Kirin in